VIRGINIA RETIREMENT SYSTEMS ET Al Invests $311,000 in Revolution Medicines, Inc. $RVMD

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Revolution Medicines, Inc. (NASDAQ:RVMD) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 3,900 shares of the company’s stock, valued at approximately $311,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Indiana Trust & Investment Management Co acquired a new position in Revolution Medicines in the fourth quarter valued at $32,000. Torren Management LLC purchased a new stake in shares of Revolution Medicines in the fourth quarter worth about $33,000. Darwin Wealth Management LLC purchased a new stake in shares of Revolution Medicines in the fourth quarter worth about $40,000. Signaturefd LLC boosted its position in shares of Revolution Medicines by 33.1% in the fourth quarter. Signaturefd LLC now owns 656 shares of the company’s stock worth $52,000 after buying an additional 163 shares during the period. Finally, CWM LLC lifted its stake in shares of Revolution Medicines by 51.6% in the fourth quarter. CWM LLC now owns 702 shares of the company’s stock worth $56,000 after acquiring an additional 239 shares in the last quarter. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Revolution Medicines Stock Up 2.0%

Shares of Revolution Medicines stock opened at $147.30 on Wednesday. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.19. Revolution Medicines, Inc. has a 1 year low of $34.00 and a 1 year high of $155.70. The stock has a 50-day moving average price of $120.60 and a 200 day moving average price of $99.54. The company has a market cap of $31.32 billion, a P/E ratio of -20.83 and a beta of 1.41.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($2.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same period last year, the firm posted ($1.13) earnings per share. As a group, analysts expect that Revolution Medicines, Inc. will post -7.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on RVMD. Benchmark reiterated an “overweight” rating on shares of Revolution Medicines in a research note on Tuesday, February 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Revolution Medicines in a research report on Tuesday, April 21st. UBS Group initiated coverage on Revolution Medicines in a research report on Friday, February 27th. They set a “buy” rating on the stock. Royal Bank Of Canada increased their price objective on Revolution Medicines to $165.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Finally, Jefferies Financial Group initiated coverage on Revolution Medicines in a report on Monday, March 16th. They issued a “buy” rating for the company. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $108.88.

Insider Buying and Selling at Revolution Medicines

In other news, insider Stephen Michael Kelsey sold 4,302 shares of the firm’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $427,962.96. Following the transaction, the insider owned 295,398 shares in the company, valued at approximately $29,386,193.04. This trade represents a 1.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Lin Wei sold 2,073 shares of the business’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $206,222.04. Following the completion of the sale, the insider directly owned 101,366 shares of the company’s stock, valued at $10,083,889.68. This represents a 2.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 184,592 shares of company stock worth $24,499,532 in the last ninety days. Company insiders own 8.20% of the company’s stock.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.